SAMHD1 and central nervous system cancer: The ANOVA yielded a significant p-value of 0.018, and in a pair-wise comparison with Tukey-Kramer’s post-hoc test, samples obtained from GBM patients showed a significantly elevated SAMHD1 level compared to both lower-grade gliomas and non-tumor brain samples (Figure 1A).